Join Dima Romashin, CEO and Co-Founder of Efferon, for an unvarnished examination of the execution bottleneck threatening modern life sciences. While the biotech sector is experiencing an unprecedented boom in discovery, an industry-wide crisis looms at the industrialization layer: brilliant therapeutics and medical devices frequently fail not because the science is flawed, but because it cannot be reliably replicated at scale. Bringing a background as a manufacturing executive at a $100M+ enterprise to the deep-tech ecosystem, Dima argues that true clinical impact only occurs when a breakthrough can be successfully manufactured by the millions. In this episode, we explore how Efferon is scaling its revolutionary blood purification platform and redefining the rules of biotech capital formation.

🎯 Insights You’ll Learn:

The Scale-Up M ...